CervoMed, Inc.

As of May 10, 2023, CervoMed, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 1.91, an EV to EBIT of -1.48, a ROE of -53.91%, and a 1-year stock return of -67.27%, significantly underperforming its peers and the S&P 500.

As of June 17, 2025, the technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and Bollinger Bands, a bearish monthly RSI, and overall declines in the stock over the past year and three years, despite some mildly bullish daily moving averages.

CervoMed, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that improve radiation and chemotherapy effectiveness by targeting tumor oxygen deprivation. It has a market cap of $61.44 million, with recent net sales of $2 million and a net loss of $5 million.

As of Jun 18, CervoMed, Inc. has a market capitalization of 61.44 million, with net sales of 9.31 million and a net profit of -18.67 million over the latest four quarters. The company reported shareholder's funds of 39.20 million and total assets of 43.46 million as of Dec 24.